A small beat with a larger meaning
On paper, the gap between Straumann's 667.1 million Swiss francs in quarterly revenue and the 662.3 million consensus compiled by Vara is narrow, less than 1%. But in a year shaped by a strong franc, trade frictions and uncertain consumer spending, consistency is itself a form of strength. The Basel-based group has now met or beaten expectations in every quarter of 2026, after organic growth of 7.1% in the first quarter and 8.5% in the second.
Management reaffirmed its targets for the year: organic revenue growth in the high single digits and an improvement in the core operating margin of 140 to 170 basis points at constant currency. Key figures from the quarter include:
- Group revenue: CHF 667.1 million, against a consensus of CHF 662.3 million
- North America: organic growth of 7.5%, up from 5.7% a year earlier
- Asia-Pacific: organic growth of 10.3%, compared with 3.2% a year earlier
- Full-year outlook: confirmed, with no disruption expected in the fourth quarter
North America: steadier ground under high rates
For an implant maker, few markets matter as much as the United States, where treatment is largely paid out of pocket and therefore sensitive to borrowing costs and household budgets. Daniellot told Reuters that elevated interest rates were still weighing on patient demand, but that conditions had stabilised compared with previous quarters, a view backed by organic growth that accelerated even as tariffs added costs.















